title: Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population.
abstract: BACKGROUND
  Several investigations have reported that abnormalities in circadian rhythms might be related to the pathophysiology of major depressive disorder (MDD) and the therapeutic response to selective serotonin reuptake inhibitors (SSRIs). Recently, ubiquitin-specific peptidase 46 (USP46), a new molecule related to the circadian clock system, has been described. We conducted a case control study between seven tagging SNPs (rs10517263, rs17675844, rs6554557, rs12646800, rs2244291, rs10034164, rs346005) in the USP46 gene, MDD, and the SSRI therapeutic response in MDD in the Japanese population.
  
  
  METHODS
  We recruited 432 MDD patients (202 males and 230 females) and 792 healthy controls (319 males and 473 females). Two hundred sixty-one of 432 MDD patients were treated with SSRIs (fluvoxamine, sertraline or paroxetine).
  
  
  RESULTS
  We detected an association between the USP46 gene and MDD in a haplotype analysis (rs2244291-rs10034164-rs346005 and rs12646800-rs2244291-rs10034164-rs346005). However, we did not find any association between the USP46 gene and SSRI response or remission in MDD in the Japanese population.
  
  
  CONCLUSIONS
  A replication study using larger samples may be required for conclusive results, since our sample size was small.
  
  
  CONCLUSIONS
  Our results suggest that the USP46 gene might play a role in the pathophysiology of MDD in the Japanese population.
authors.affiliation: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fukuo
authors.forename: Taro
authors.initials: T
authors.lastname: Kishi
authors.forename: Itaru
authors.initials: I
authors.lastname: Kushima
authors.forename: Reiji
authors.initials: R
authors.lastname: Yoshimura
authors.forename: Tomo
authors.initials: T
authors.lastname: Okochi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kitajima
authors.forename: Shinji
authors.initials: S
authors.lastname: Matsunaga
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Kawashima
authors.forename: Wakako
authors.initials: W
authors.lastname: Umene-Nakano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Naitoh
authors.forename: Toshiya
authors.initials: T
authors.lastname: Inada
authors.forename: Jun
authors.initials: J
authors.lastname: Nakamura
authors.forename: Norio
authors.initials: N
authors.lastname: Ozaki
authors.forename: Nakao
authors.initials: N
authors.lastname: Iwata
mesh_terms: D000328:Adult; D044466:Asian People / Q000235:genetics; D016022:Case-Control Studies; D057906:Circadian Clocks; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000208:ethnology / Q000235:genetics*; D010450:Endopeptidases / Q000235:genetics*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D020280:Sertraline / Q000627:therapeutic use; D016896:Treatment Outcome; D025801:Ubiquitin / Q000235:genetics / Q000627:therapeutic use
chemical_list: D010450:Endopeptidases; D016666:Fluvoxamine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D025801:Ubiquitin; C562185:ubiquitin-specific peptidase 46, human